ImmunisBio Advances Immune Cell Therapy into Malaysia

Published 12 Mar.2020 10:31(KST)

[Asia Economy Reporter Hyungsoo Park] Immunis Bio announced on the 12th that it has signed a technology export contract for the immune cell therapy (MYJ1633) with Malaysia's NK Biosell.

NK Biosell, headquartered in Malaysia, is a specialized company in immune cell therapy and stem cell therapy.

By signing the technology export contract, Immunis Bio expects to provide treatment using the cell therapy (MYJ1633) in Malaysia. According to the contract, researchers will be dispatched locally in Malaysia, and core solutions will also be exported. They will receive all educational expenses related to technology transfer and running royalties on sales revenue. The core solutions and raw materials used in the manufacturing of the cell therapy will be supplied exclusively.

MYJ1633, which is the second technology export following Vietnam, is an immune cell therapy for hematologic and solid cancers. It is being administered to cancer patients in Japan and Vietnam. Based on excellent technology, it is an autologous NK cell therapy cultured without concerns about DNA modification or side effects. It has superior anticancer and anti-aging effects.

Kang Jung-hwa, CEO of Immunis Bio, said, "It is significant that our cell therapy, which is bearing fruit in the immune cell therapy market, is pioneering a new market following Japan and Vietnam," adding, "We will achieve meaningful results in the Malaysian cell therapy market through cooperation with our partner company."

NK Biosell of Malaysia introduced, "It is estimated that about 85,000 new cancer patients are registered annually among the Malaysian population," and "Except for breast cancer, the proportion of colorectal and lung cancers, which are under clinical trials by Immunis Bio, is as high as about 28%."

Since 2003, Malaysia has been fostering the medical tourism industry led by the government. Based on price competitiveness, it provides high-quality medical services, attracting increasing numbers of patients from neighboring countries such as Thailand, Singapore, and Indonesia.